Tumour-Infiltrating Clonal Haematopoiesis Increases the Risk of Recurrence or Death Among Patients with NSCLC and the Risk of Death From Any Cause Among Patients with Solid Tumours By Ogkologos - May 7, 2025 715 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the analysis of TRACERx and MSK-IMPACT studies Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Adjuvant Nivolumab Prolongs DFS in Patients with Resected Osophageal or Gastroesophageal... April 6, 2021 Study Identifies Hundreds of Potential Targets for Cancer Drugs September 11, 2024 Promoting Inclusion for LGBTQ+ People With Cancer: “Your Stories” Podcast September 21, 2021 Plans for NCI’s Fiscal Year 2019 Budget December 18, 2018 Load more HOT NEWS New Imaging Tool Could Predict Whether Hormone Therapy Will Work in... Using Immunotherapy to Treat Advanced Melanoma and Advanced Non-Small Cell Lung... New Combination of Old Drugs Improves Survival in Patients with Prostate... No Link Between Caffeine Consumption and Breast Cancer, Study Finds
